Skip to content
HowShorted

Intra-Cellular Therapies Inc. short interest in 2021

In 2021, Intra-Cellular Therapies Inc.'s disclosed short interest ran from 8.62% of shares outstanding on 15 Jan 2021 to 5.57% on 31 Dec 2021, a change of -3.05 percentage points. The year's high was 8.62% on 15 Jan 2021 and its low 4.43% on 30 Nov 2021, averaging 6.99% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.37 days on 15 Apr 2021. Full history: Intra-Cellular Therapies Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Intra-Cellular Therapies Inc. in 2021

2021 in figures

Start of year
8.62% (15 Jan 2021)
End of year
5.57% (31 Dec 2021)
Change
-3.05 pp
High
8.62% (15 Jan 2021)
Low
4.43% (30 Nov 2021)
Average
6.99%
Highest days to cover
18.37 (15 Apr 2021)
SEC filings marked
8

Every report in 2021

Intra-Cellular Therapies Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20218.62%11.38
29 Jan 20218.32%10.34
12 Feb 20217.93%11.41
26 Feb 20218.02%10.2210-K filed, results (8-K)
15 Mar 20217.90%12.42
31 Mar 20217.82%14.05
15 Apr 20217.79%18.37
30 Apr 20218.52%15.03
14 May 20218.41%11.2610-Q filed, results (8-K)
28 May 20217.71%17.75
15 Jun 20217.25%12.80
30 Jun 20216.36%7.15
15 Jul 20217.11%16.13
30 Jul 20216.91%12.53
13 Aug 20216.72%11.5410-Q filed, results (8-K)
31 Aug 20217.19%12.25
15 Sep 20217.19%17.78
30 Sep 20217.10%12.28
15 Oct 20216.57%16.04
29 Oct 20215.17%9.66
15 Nov 20214.53%6.7410-Q filed, results (8-K)
30 Nov 20214.43%7.12
15 Dec 20214.53%7.23
31 Dec 20215.57%2.96

See also: Intra-Cellular Therapies Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.